公开(公告)号：US12297269B2

公开(公告)日：2025-05-13

申请号：US17417570

申请日：2019-12-24

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Olga Vladimirovna Britanova ,  Dmitry Borisovich Staroverov ,  Anna Valentinovna Evstrateva ,  Alexey Konstantinovich Misorin ,  Timofey Aleksandrovich Nemankin ,  Mariia Aleksandrovna Shchemeleva ,  Anna Konstantinovna Vladimirova ,  Arina Vitalevna Anikina ,  Roman Alekseevich Ivanov ,  Dmitry Valentinovich Morozov ,  Pavel Andreevich Iakovlev ,  Sergey Anatolievich Lukyanov

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06

Abstract: A monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. A nucleic acid encoding the antibody or antigen-binding fragment thereof, an expression vector, a method for preparing the antibody, and use of the antibody in treatment of diseases or disorders associated with the human T cell receptor family. The generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

公开(公告)号：US12227572B2

公开(公告)日：2025-02-18

申请号：US17417686

申请日：2020-02-20

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Olga Vladimirovna Britanova ,  Dmitry Borisovich Staroverov ,  Anna Valentinovna Evstrateva ,  Alexey Konstantinovich Misorin ,  Timofey Aleksandrovich Nemankin ,  Mariia Aleksandrovna Shchemeleva ,  Anna Konstantinovna Vladimirova ,  Arina Vitalevna Anikina ,  Roman Alekseevich Ivanov ,  Dmitry Valentinovich Morozov ,  Pavel Andreevich Iakovlev ,  Sergey Anatolievich Lukyanov

IPC: C07K16/28 ,  A61K39/00

Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.